Endologix (NASDAQ: ELGX) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it compare to its competitors? We will compare Endologix to similar companies based on the strength of its analyst recommendations, valuation, profitability, earnings, institutional ownership, risk and dividends.

Analyst Recommendations

This is a summary of recent recommendations for Endologix and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Endologix 0 8 0 0 2.00
Endologix Competitors 111 728 1026 10 2.50

Endologix currently has a consensus price target of $5.69, indicating a potential upside of 11.30%. As a group, “Medical Devices & Implants” companies have a potential upside of 36.81%. Given Endologix’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Endologix has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

54.8% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 4.1% of Endologix shares are held by insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Endologix has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Endologix’s competitors have a beta of 0.30, meaning that their average share price is 71% less volatile than the S&P 500.

Profitability

This table compares Endologix and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Endologix -41.60% -52.18% -13.70%
Endologix Competitors -101.23% -92.70% -30.32%

Valuation and Earnings

This table compares Endologix and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Endologix $192.93 million -$154.67 million -5.49
Endologix Competitors $1.67 billion $207.58 million 80.90

Endologix’s competitors have higher revenue and earnings than Endologix. Endologix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Endologix competitors beat Endologix on 8 of the 12 factors compared.

About Endologix

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.